{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T20:09:54Z","timestamp":1790885394739,"version":"4.1.0"},"reference-count":128,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council of Taiwan","doi-asserted-by":"crossref","award":["114-2320-B-038-012"],"award-info":[{"award-number":["114-2320-B-038-012"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100022290","name":"Office of Research and Development, Taipei Medical University","doi-asserted-by":"publisher","award":["TMU113-AE1-B16"],"award-info":[{"award-number":["TMU113-AE1-B16"]}],"id":[{"id":"10.13039\/501100022290","id-type":"DOI","asserted-by":"publisher"}]},{"name":"TMU\u2013Ji Yan Biomedical Co., Ltd. Industry\u2013Academia Collaboration Project","award":["A-114-041"],"award-info":[{"award-number":["A-114-041"]}]},{"name":"TMU\u2013Ji Yan Biomedical Co., Ltd. Industry\u2013Academia Collaboration Project","award":["A-113-086"],"award-info":[{"award-number":["A-113-086"]}]},{"name":"Sunny Brain Tumor and Brain Disease Research and Development Fund","award":["106-5310-001-400"],"award-info":[{"award-number":["106-5310-001-400"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"DOI":"10.1007\/s00262-026-04372-5","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T14:19:56Z","timestamp":1775830796000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Targeting the COX-2\/PGE2 axis to enhance NK and T cell immunotherapy in brain tumors"],"prefix":"10.1007","volume":"75","author":[{"given":"Chih-Jie","family":"Shen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joy","family":"Florentino-Krasnov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"You-Cheng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Wen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bahagia Willibrordus Maria","family":"Nainggolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yung-Hsiao","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-I.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"key":"4372_CR1","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1038\/s41388-023-02738-y","volume":"42","author":"D Eisenbarth","year":"2023","unstructured":"Eisenbarth D, Wang YA (2023) Glioblastoma heterogeneity at single cell resolution. Oncogene 42:2155\u20132165","journal-title":"Oncogene"},{"key":"4372_CR2","doi-asserted-by":"publisher","first-page":"1003651","DOI":"10.3389\/fimmu.2022.1003651","volume":"13","author":"X Zhang","year":"2022","unstructured":"Zhang X, Zhao L, Zhang H, Zhang Y, Ju H, Wang X et al (2022) The immunosuppressive microenvironment and immunotherapy in human glioblastoma. Front Immunol 13:1003651","journal-title":"Front Immunol"},{"key":"4372_CR3","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhou F, Ali H, Lathia JD, Chen P (2024) Immunotherapy for glioblastoma: current state, challenges, and future perspectives. Cell Mol Immunol 21:1354\u20131375","journal-title":"Cell Mol Immunol"},{"key":"4372_CR4","first-page":"910595","volume":"13","author":"B Seliger","year":"2022","unstructured":"Seliger B, Koehl U (2022) Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies. Front Oncol 13:910595","journal-title":"Front Oncol"},{"key":"4372_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25137174","author":"E Agosti","year":"2024","unstructured":"Agosti E, Garaba A, Antonietti S, Ius T, Fontanella MM, Zeppieri M et al (2024) CAR-T cells therapy in glioblastoma: a systematic review on molecular targets and treatment strategies. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms25137174","journal-title":"Int J Mol Sci"},{"key":"4372_CR6","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1093\/neuonc\/noad087","volume":"25","author":"MC Burger","year":"2023","unstructured":"Burger MC, Forster MT, Romanski A, Strassheimer F, Macas J, Zeiner PS et al (2023) Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma. Neuro Oncol 25:2058\u20132071","journal-title":"Neuro Oncol"},{"key":"4372_CR7","doi-asserted-by":"publisher","first-page":"1434495","DOI":"10.3389\/fonc.2024.1434495","volume":"14","author":"RC Sterner","year":"2024","unstructured":"Sterner RC, Sterner RM (2024) EGFRVIII and EGFR targeted chimeric antigen receptor T cell therapy in glioblastoma. Front Oncol 14:1434495","journal-title":"Front Oncol"},{"key":"4372_CR8","doi-asserted-by":"publisher","first-page":"1116014","DOI":"10.3389\/fonc.2022.1116014","volume":"12","author":"PT Dean","year":"2022","unstructured":"Dean PT, Hooks SB (2022) Pleiotropic effects of the COX-2\/PGE2 axis in the glioblastoma tumor microenvironment. Front Oncol 12:1116014","journal-title":"Front Oncol"},{"key":"4372_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202506336","author":"CJ Shen","year":"2025","unstructured":"Shen CJ, Chen HC, Lin CL, Thakur A, Onuku R, Chen IC et al (2025) Contribution of prostaglandin E2-induced neuronal excitation to drug resistance in glioblastoma countered by a novel blood-brain barrier crossing celecoxib derivative. Adv Sci. https:\/\/doi.org\/10.1002\/advs.202506336","journal-title":"Adv Sci"},{"key":"4372_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010146","author":"D Sipos","year":"2025","unstructured":"Sipos D, Raposa BL, Freihat O, Simon M, Mekis N, Cornacchione P et al (2025) Glioblastoma: clinical presentation, multidisciplinary management, and long-term outcomes. Cancers. https:\/\/doi.org\/10.3390\/cancers17010146","journal-title":"Cancers"},{"key":"4372_CR11","doi-asserted-by":"publisher","first-page":"216711","DOI":"10.1016\/j.canlet.2024.216711","volume":"588","author":"E Miele","year":"2024","unstructured":"Miele E, Anghileri E, Calatozzolo C, Lazzarini E, Patrizi S, Ciolfi A et al (2024) Clinicopathological and molecular landscape of 5-year IDH-wild-type glioblastoma survivors: a multicentric retrospective study. Cancer Lett 588:216711","journal-title":"Cancer Lett"},{"key":"4372_CR12","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1016\/j.ymthe.2025.02.043","volume":"33","author":"P Poorva","year":"2025","unstructured":"Poorva P, Mast J, Cao B, Shah MV, Pollok KE, Shen J (2025) Killing the killers: natural killer cell therapy targeting glioma stem cells in high-grade glioma. Mol Ther 33:2462\u20132478","journal-title":"Mol Ther"},{"key":"4372_CR13","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/s41698-025-01059-5","volume":"9","author":"AJ Groth","year":"2025","unstructured":"Groth AJ, Khasraw M, Byrne JD, Reitman ZJ (2025) Enhancing adoptive cell therapy: future strategies for immune cell radioprotection in neuro-oncology. npj Precis Oncol 9:264","journal-title":"npj Precis Oncol"},{"key":"4372_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cimb47060417","author":"M Garcia-Dominguez","year":"2025","unstructured":"Garcia-Dominguez M (2025) Neuroinflammation: mechanisms, dual roles, and therapeutic strategies in neurological disorders. Curr Issues Mol Biol. https:\/\/doi.org\/10.3390\/cimb47060417","journal-title":"Curr Issues Mol Biol"},{"key":"4372_CR15","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41392-025-02241-8","volume":"10","author":"T Pu","year":"2025","unstructured":"Pu T, Sun J, Ren G, Li H (2025) Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications. Signal Transduct Target Ther 10:176","journal-title":"Signal Transduct Target Ther"},{"key":"4372_CR16","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.3389\/fimmu.2019.01314","volume":"10","author":"N Priego","year":"2019","unstructured":"Priego N, Valiente M (2019) The potential of astrocytes as immune modulators in brain tumors. Front Immunol 10:1314","journal-title":"Front Immunol"},{"key":"4372_CR17","doi-asserted-by":"crossref","unstructured":"Wang J, Toregrosa-Allen S, Elzey BD, Utturkar S, Lanman NA, Bernal-Crespo V, et al. (2021) Multispecific targeting of glioblastoma with tumor microenvironment-responsive multifunctional engineered NK cells. Proc Natl Acad Sci U S A 118: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34740973","DOI":"10.1073\/pnas.2107507118"},{"key":"4372_CR18","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.3389\/fimmu.2018.01345","volume":"9","author":"HN Haspels","year":"2018","unstructured":"Haspels HN, Rahman MA, Joseph JV, Gras Navarro A, Chekenya M (2018) G glioblastoma stem-like cells are more susceptible than differentiated cells to natural killer cell lysis mediated through killer immunoglobulin-like receptors-human leukocyte antigen ligand mismatch and activation receptor-ligand interactions. Front Immunol 9:1345","journal-title":"Front Immunol"},{"key":"4372_CR19","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1101\/gad.349538.122","volume":"36","author":"T Eisemann","year":"2022","unstructured":"Eisemann T, Wechsler-Reya RJ (2022) Coming in from the cold: overcoming the hostile immune microenvironment of medulloblastoma. Genes Dev 36:514\u2013532","journal-title":"Genes Dev"},{"key":"4372_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16233942","author":"G Dao Nyesiga","year":"2024","unstructured":"Dao Nyesiga G, Haslund-Vinding JL, Budde J, Lange JF, Blum N, Dukstaite K et al (2024) Flow cytometry analyses of meningioma immune cell composition using a short, optimized digestion protocol. Cancers. https:\/\/doi.org\/10.3390\/cancers16233942","journal-title":"Cancers"},{"key":"4372_CR21","doi-asserted-by":"crossref","unstructured":"Monje M, Mahdi J, Majzner R, Yeom KW, Schultz LM, Richards RM, et al (2025) Intravenous and intracranial GD2-CAR T cells for H3K27M(+) diffuse midline gliomas. Nature 637:708\u2013715. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39537919","DOI":"10.1038\/s41586-024-08171-9"},{"key":"4372_CR22","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.trecan.2023.07.007","volume":"9","author":"BC Thomas","year":"2023","unstructured":"Thomas BC, Staudt DE, Douglas AM, Monje M, Vitanza NA, Dun MD (2023) CAR T cell therapies for diffuse midline glioma. Trends Cancer 9:791\u2013804","journal-title":"Trends Cancer"},{"key":"4372_CR23","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","volume":"8","author":"S Chen","year":"2023","unstructured":"Chen S, Saeed A, Liu Q, Jiang Q, Xu H, Xiao GG et al (2023) Macrophages in immunoregulation and therapeutics. Signal Transduct Target Ther 8:207","journal-title":"Signal Transduct Target Ther"},{"key":"4372_CR24","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2741\/4573","volume":"22","author":"SY Wu","year":"2017","unstructured":"Wu SY, Watabe K (2017) The roles of microglia\/macrophages in tumor progression of brain cancer and metastatic disease. Front Biosci 22:1805\u20131829","journal-title":"Front Biosci"},{"key":"4372_CR25","doi-asserted-by":"publisher","first-page":"680021","DOI":"10.3389\/fphar.2021.680021","volume":"12","author":"MS Alghamri","year":"2021","unstructured":"Alghamri MS, McClellan BL, Hartlage CS, Haase S, Faisal SM, Thalla R et al (2021) Targeting neuroinflammation in brain cancer: uncovering mechanisms, pharmacological targets, and neuropharmaceutical developments. Front Pharmacol 12:680021","journal-title":"Front Pharmacol"},{"key":"4372_CR26","doi-asserted-by":"publisher","first-page":"1600403","DOI":"10.3389\/fimmu.2025.1600403","volume":"16","author":"Y Kaminskiy","year":"2025","unstructured":"Kaminskiy Y, Degtyarev V, Stepanov A, Maschan M (2025) CAR T cell therapy for central nervous system solid tumors: current progress and future directions. Front Immunol 16:1600403","journal-title":"Front Immunol"},{"key":"4372_CR27","doi-asserted-by":"publisher","first-page":"1541467","DOI":"10.3389\/fimmu.2025.1541467","volume":"16","author":"H Su","year":"2025","unstructured":"Su H, Peng Y, Wu Y, Zeng X (2025) Overcoming immune evasion with innovative multi-target approaches for glioblastoma. Front Immunol 16:1541467","journal-title":"Front Immunol"},{"key":"4372_CR28","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y et al (2021) Inflammation and tumor progression: signaling pathways and targeted intervention. Signal Transduct Target Ther 6:263","journal-title":"Signal Transduct Target Ther"},{"key":"4372_CR29","doi-asserted-by":"crossref","unstructured":"Dana N, Dabiri A, Najafi MB, Rahimi A, Ishaghi SMM, Shariati L, et al. (2025) Advances in bioengineered CAR T\/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T\/NK cell therapy. Bioeng Transl Med 10:e10716. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40060757","DOI":"10.1002\/btm2.10716"},{"key":"4372_CR30","doi-asserted-by":"crossref","unstructured":"Huang Y, Liao H, Luo J, Wei H, Li A, Lu Y, et al. (2024) Reversing NK cell exhaustion: a novel strategy combining immune checkpoint blockade with drug sensitivity enhancement in the treatment of hepatocellular carcinoma. Front Oncol 14:1502270. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39906665","DOI":"10.3389\/fonc.2024.1502270"},{"key":"4372_CR31","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1038\/s41392-025-02280-1","volume":"10","author":"M Tufail","year":"2025","unstructured":"Tufail M, Jiang CH, Li N (2025) Immune evasion in cancer: mechanisms and cutting-edge therapeutic approaches. Signal Transduct Target Ther 10:227","journal-title":"Signal Transduct Target Ther"},{"key":"4372_CR32","doi-asserted-by":"publisher","first-page":"7047","DOI":"10.1038\/s41598-021-86219-w","volume":"11","author":"C Garcia-Pastor","year":"2021","unstructured":"Garcia-Pastor C, Benito-Martinez S, Bosch RJ, Fernandez-Martinez AB, Lucio-Cazana FJ (2021) Intracellular prostaglandin E2 contributes to hypoxia-induced proximal tubular cell death. Sci Rep 11:7047","journal-title":"Sci Rep"},{"key":"4372_CR33","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1215\/15228517-2008-035","volume":"10","author":"N Baryawno","year":"2008","unstructured":"Baryawno N, Sveinbjornsson B, Eksborg S, Orrego A, Segerstrom L, Oqvist CO et al (2008) Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets. Neuro Oncol 10:661\u2013674","journal-title":"Neuro Oncol"},{"key":"4372_CR34","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1038\/s41417-024-00762-y","volume":"31","author":"C Wang","year":"2024","unstructured":"Wang C, Fu R, Wang Y, Wei J, Yu Y, Hu L et al (2024) miR-124-3p and miR-194-5p regulation of the PI3K\/AKT pathway via ROR2 in medulloblastoma progression. Cancer Gene Ther 31:941\u2013954","journal-title":"Cancer Gene Ther"},{"key":"4372_CR35","doi-asserted-by":"publisher","first-page":"9464","DOI":"10.1038\/s41467-024-53706-3","volume":"15","author":"S Punyawatthananukool","year":"2024","unstructured":"Punyawatthananukool S, Matsuura R, Wongchang T, Katsurada N, Tsuruyama T, Tajima M et al (2024) Prostaglandin E(2)-EP2\/EP4 signaling induces immunosuppression in human cancer by impairing bioenergetics and ribosome biogenesis in immune cells. Nat Commun 15:9464","journal-title":"Nat Commun"},{"key":"4372_CR36","unstructured":"Phase I study of cellular immunotx using memory enriched T Cells lentivirally transduced to express an IL13R\u03b12-specific, hinge-optimized, 41BB-costimulatory chimeric receptor and a truncated CD19 for Pts With Rec\/Ref MaligGlioma (2014) In: I. National Cancer, Food, A. Drug (Eds.)"},{"key":"4372_CR37","unstructured":"A phase I\/II study of the safety and feasibility of administering T cells expressing anti-EGFRvIII chimeric antigen receptor to patients with malignant gliomas expressing EGFRvIII (2011)"},{"key":"4372_CR38","unstructured":"Pilot Feasibility and Safety Study of Cellular Immunotherapy for Recurrent\/Refractory Malignant Glioma Using Genetically-Modified Autologous CD8+ T Cell Clones, in: I. National Cancer (Ed.) (2008)"},{"key":"4372_CR39","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/s41698-024-00753-0","volume":"8","author":"S Park","year":"2024","unstructured":"Park S, Maus MV, Choi BD (2024) CAR-T cell therapy for the treatment of adult high-grade gliomas. npj Precis Oncol 8:279","journal-title":"npj Precis Oncol"},{"key":"4372_CR40","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1038\/s41591-024-02893-z","volume":"30","author":"SJ Bagley","year":"2024","unstructured":"Bagley SJ, Logun M, Fraietta JA, Wang X, Desai AS, Bagley LJ et al (2024) Intrathecal bivalent CAR T cells targeting EGFR and IL13Ralpha2 in recurrent glioblastoma: phase 1 trial interim results. Nat Med 30:1320\u20131329","journal-title":"Nat Med"},{"key":"4372_CR41","unstructured":"Phase 1 study of autologous anti-EGFRvIII synNotch receptor induced anti-EphA2\/IL-13R alpha2 CAR (E-SYNC) T Cells in adult participants With EGFRvIII+ Glioblastoma. (2023) In: M. California Institute for Regenerative,I. national cancer (Eds.)"},{"key":"4372_CR42","unstructured":"A phase I study of autologous activated natural killer (NK) Cells +\/- rhIL15 in children and young adults with refractory solid tumors (2013)"},{"key":"4372_CR43","unstructured":"Phase 2 solid tumor immunotherapy trial using HLA-haploidentical transplant and donor natural killer cells: the STIR trial (2014)"},{"key":"4372_CR44","unstructured":"A pilot study of immunotherapy including haploidentical NK cell infusion following CD133+ positively-selected autologous hematopoietic stem cells in children with high risk solid tumors or lymphomas (2014)"},{"key":"4372_CR45","unstructured":"A Phase I Study to investigate tolerability and efficacy of autologous lymphoid effector cells specific against tumour-cells (ALECSAT) Administered to Patients With Glioblastoma Multiforme (GBM) (2012)"},{"key":"4372_CR46","unstructured":"Multicenter, Open Label, Phase I Study of intracranial injection of NK-92\/5.28.z cells in patients With Recurrent HER2-positive Glioblastoma. (2017) In: D.R.K.B.B.-W.-H. gGmbH, H. Georg Speyer, L.C.F.C. Institute, C. German Cancer Research (Eds.)"},{"key":"4372_CR47","unstructured":"Study evaluating the efficacy and safety of chimeric antigen receptor-modified pNK cells in MUC1 positive advanced refractory or relapsed solid tumor. (2016) In: H. The First People\u2019s Hospital of, H. Hefei Binhu (Eds.)"},{"key":"4372_CR48","unstructured":"Phase 1 Study of B7-H3-Specific CAR T cell locoregional immunotherapy for diffuse intrinsic pontine glioma\/diffuse midline glioma and recurrent or refractory pediatric central nervous system tumors (2019)"},{"key":"4372_CR49","unstructured":"Phase 1 Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T cell locoregional immunotherapy for pediatric diffuse intrinsic pontine glioma, diffuse midline glioma, and recurrent or refractory central nervous system tumors (2023)"},{"key":"4372_CR50","unstructured":"Study of Natural Killer Cell Combined With Chemotherapy for Advanced Solid Tumor (2019)"},{"key":"4372_CR51","unstructured":"Pilot Study of Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma. (2014) In: S.F. University of California (Ed.)"},{"key":"4372_CR52","unstructured":"A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed\/Refractory NKG2DL+ Solid Tumors. (2020) In: Kaedi (Ed.)"},{"key":"4372_CR53","unstructured":"Pilot Study of UWNKG2D CAR-T in Treating Patients With Recurrent Glioblastoma (2021)"},{"key":"4372_CR54","unstructured":"A Phase I Clinical Trial of NKG2D-based CAR T-cells Injection for Subjects With Relapsed\/Refractory NKG2DL+ Solid Tumors. (2021) In: Kaedi (Ed.)"},{"key":"4372_CR55","unstructured":"Pilot Study of NKG2D-Ligand Targeted CAR-NK Cells in Patients With Metastatic Solid Tumours (2018)"},{"key":"4372_CR56","unstructured":"Immunotherapy With Ex Vivo-Expanded Cord Blood-Derived CAR-NK Cells Combined With High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-Cell Lymphoma (2018) In: I. National Cancer (Ed.)"},{"key":"4372_CR57","unstructured":"One-center, Open-label, Single-arm Clinical Study of the Safety and Effectiveness of NKG2D CAR-T Cells Infusion in the Treatment of Relapsed\/ Refractory NKG2DL+ Tumors (2020) In: Kaedi (Ed.)"},{"key":"4372_CR58","unstructured":"B7-H3-targeted chimeric antigen receptor (CAR) T cells in treating patients with recurrent or refractory glioblastoma (2019) In: H. Ningbo Yinzhou People\u2019s, H. Huizhou Municipal Central, L. BoYuan RunSheng Pharma Co (Eds.)."},{"key":"4372_CR59","unstructured":"Dose escalation study phase I\/II of umbilical cord blood-derived car-engineered NK cells in conjunction with lymphodepleting chemotherapy in patients with relapsed\/refractory B-lymphoid malignancies (2017)"},{"key":"4372_CR60","unstructured":"A phase 1b study to evaluate CHM-1101, a CAR T-cell therapy with a chlorotoxin tumor-targeting domain for patients with matrix metallopeptidase 2 Positive (MMP2+) recurrent or progressive glioblastoma Multiforme (2022)"},{"key":"4372_CR61","doi-asserted-by":"publisher","first-page":"1648601","DOI":"10.3389\/fimmu.2025.1648601","volume":"16","author":"W Zhang","year":"2025","unstructured":"Zhang W, Zhang W, Wu H, Han X (2025) Harnessing innate immunity against glioblastoma microenvironment. Front Immunol 16:1648601","journal-title":"Front Immunol"},{"key":"4372_CR62","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1093\/neuonc\/noy084","volume":"21","author":"NM Ratnam","year":"2019","unstructured":"Ratnam NM, Gilbert MR, Giles AJ (2019) Immunotherapy in CNS cancers: the role of immune cell trafficking. Neuro Oncol 21:37\u201346","journal-title":"Neuro Oncol"},{"key":"4372_CR63","doi-asserted-by":"crossref","unstructured":"Grant G, Ferrer CM (2025) The role of the immune tumor microenvironment in shaping metastatic dissemination, dormancy, and outgrowth. Trends Cell Biol https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40628544","DOI":"10.1016\/j.tcb.2025.05.006"},{"key":"4372_CR64","doi-asserted-by":"crossref","unstructured":"Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al (2025) Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther 10:213. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40628732","DOI":"10.1038\/s41392-025-02299-4"},{"key":"4372_CR65","doi-asserted-by":"publisher","first-page":"1489827","DOI":"10.3389\/fimmu.2024.1489827","volume":"15","author":"SH Khan","year":"2024","unstructured":"Khan SH, Choi Y, Veena M, Lee JK, Shin DS (2024) Advances in CAR T cell therapy: antigen selection, modifications, and current trials for solid tumors. Front Immunol 15:1489827","journal-title":"Front Immunol"},{"key":"4372_CR66","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1124\/pharmrev.123.000901","volume":"76","author":"A Santiso","year":"2024","unstructured":"Santiso A, Heinemann A, Kargl J (2024) Prostaglandin E2 in the tumor microenvironment, a convoluted affair mediated by EP receptors 2 and 4. Pharmacol Rev 76:388\u2013413","journal-title":"Pharmacol Rev"},{"key":"4372_CR67","doi-asserted-by":"publisher","first-page":"1355769","DOI":"10.3389\/fimmu.2024.1355769","volume":"15","author":"J Cuenca-Escalona","year":"2024","unstructured":"Cuenca-Escalona J, Subtil B, Garcia-Perez A, Cambi A, de Vries IJM, Florez-Grau G (2024) EP2 and EP4 blockade prevents tumor-induced suppressive features in human monocytic myeloid-derived suppressor cells. Front Immunol 15:1355769","journal-title":"Front Immunol"},{"key":"4372_CR68","doi-asserted-by":"crossref","unstructured":"Ibrahim A, Mohamady Farouk Abdalsalam N, Liang Z, Kashaf Tariq H, Li R, L OA et al (2025) MDSC checkpoint blockade therapy: a new breakthrough point overcoming immunosuppression in cancer immunotherapy. Cancer Gene Ther 32:371\u2013392. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40140724","DOI":"10.1038\/s41417-025-00886-9"},{"key":"4372_CR69","doi-asserted-by":"crossref","unstructured":"Qiu J, Li Q, Li J, Zhou F, Sang P, Xia Z et al (2023) Complementary roles of EP2 and EP4 receptors in malignant glioma. Br J Pharmacol 180:2623\u20132640. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/37232020","DOI":"10.1111\/bph.16148"},{"key":"4372_CR70","unstructured":"A Cancer Research UK Phase I\/IIa Trial of HTL0039732, Given Orally as Monotherapy and in Combination With Immunotherapy or Other Approved Therapies in Participants With Advanced Solid Tumours (2023) In: U.K.L. Nxera Pharma (Ed.)"},{"key":"4372_CR71","doi-asserted-by":"crossref","unstructured":"Finetti F, Travelli C, Ercoli J, Colombo G, Buoso E, Trabalzini L (2020) Prostaglandin E2 and cancer: insight into tumor progression and immunity. Biology (Basel) 9: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33271839","DOI":"10.3390\/biology9120434"},{"key":"4372_CR72","doi-asserted-by":"crossref","unstructured":"Tian Y, Yang T, Yu S, Liu C, He M, Hu C (2018) Prostaglandin E2 increases migration and proliferation of human glioblastoma cells by activating transient receptor potential melastatin 7 channels. J Cell Mol Med 22:6327\u20136337. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/30338939","DOI":"10.1111\/jcmm.13931"},{"key":"4372_CR73","doi-asserted-by":"crossref","unstructured":"Zhang J, Wang T (2021) Immune cell landscape and immunotherapy of medulloblastoma. Pediatr Investig 5:299\u2013309. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34938973","DOI":"10.1002\/ped4.12261"},{"key":"4372_CR74","doi-asserted-by":"crossref","unstructured":"Van den Ende B, Riva M, De Smet F, Jacobs S, Hulleman E, Coosemans A (2025) Exploring the tumor microenvironment in diffuse intrinsic pontine glioma: immunological insights and therapeutic challenges. J Immunother Cancer 13: https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40514066","DOI":"10.1136\/jitc-2025-012009"},{"key":"4372_CR75","doi-asserted-by":"crossref","unstructured":"Chen S, Zhu H, Jounaidi Y (2024) Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization. Signal Transduct Target Ther 9:302. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39511139","DOI":"10.1038\/s41392-024-02005-w"},{"key":"4372_CR76","doi-asserted-by":"crossref","unstructured":"Yu J, Fu L, Wu R, Che L, Liu G, Ran Q et al (2025) Immunocytes in the tumor microenvironment: recent updates and interconnections. Front Immunol 16:1517959. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/40297580","DOI":"10.3389\/fimmu.2025.1517959"},{"key":"4372_CR77","doi-asserted-by":"crossref","unstructured":"Kozlowska AK, Tseng HC, Kaur K, Topchyan P, Inagaki A, Bui VT et al (2016) Resistance to cytotoxicity and sustained release of interleukin-6 and interleukin-8 in the presence of decreased interferon-gamma after differentiation of glioblastoma by human natural killer cells. Cancer Immunol Immunother 65:1085\u20131097. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/27439500","DOI":"10.1007\/s00262-016-1866-x"},{"key":"4372_CR78","doi-asserted-by":"crossref","unstructured":"Pedde AM, Kim H, Donakonda S, Baumann T, Bayerl F, Meiser P et al (2024) Tissue-colonizing disseminated tumor cells secrete prostaglandin E2 to promote NK cell dysfunction and evade anti-metastatic immunity. Cell Rep 43:114855. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/39541209","DOI":"10.1016\/j.celrep.2024.114855"},{"key":"4372_CR79","doi-asserted-by":"crossref","unstructured":"Lin H, Liu C, Hu A, Zhang D, Yang H, Mao Y (2024) Understanding the immunosuppressive microenvironment of glioma: mechanistic insights and clinical perspectives. J Hematol Oncol 17:31. https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/38720342","DOI":"10.1186\/s13045-024-01544-7"},{"key":"4372_CR80","unstructured":"An open-label multicenter phase 1 study of E7046 in subjects with selected advanced malignancies (2015)"},{"key":"4372_CR81","unstructured":"An open-label multicenter phase 1b Study of E7046 in combination with radiotherapy\/chemoradiotherapy (RT\/CRT) in preoperative treatment of subjects with rectum cancer (2017)"},{"key":"4372_CR82","unstructured":"An open-label multicenter phase Ib study of AN0025 in combination with pembrolizumab in patients with advanced solid tumors (2020) In: S Merck, LLC Dohme (Eds.)"},{"key":"4372_CR83","unstructured":"Phase 1\/2 study of BMS-986310 administered alone and in combination with nivolumab in participants with advanced solid tumors (2018)"},{"key":"4372_CR84","unstructured":"Phase 1 dose escalating and expansion study of ONO-4578 given as monotherapy and combinations of ONO-4578 and ONO-4538 in subjects with advanced or metastatic solid tumors (2017)"},{"key":"4372_CR85","unstructured":"15xxGCC: phase II trial of the EP4 receptor antagonist, AAT-007 (RQ-07; CJ-023,423) in advanced solid tumors (2015)"},{"key":"4372_CR86","unstructured":"An Open-label, Single-arm, Phase 1b Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in combination with pembolizumab in patients with advanced or progressive microsatellite stable (MSS) colorectal cancer (CRC) (2018) In: S Merck, LLC Dohme (Eds.)"},{"key":"4372_CR87","unstructured":"Phase 1a\/1b open label dose-escalation and expansion study of TPST-1495 as a single agent and in combination with Pembrolizumab in subjects with solid tumors (2020)"},{"key":"4372_CR88","unstructured":"A pilot trial of ifetroban, a thromboxane A2 receptor antagonist, in patients with malignant solid tumors at high risk of metastatic recurrence (2018) In: P Cumberland (Ed.)"},{"key":"4372_CR89","unstructured":"An open-label, single-arm, phase Ib\/IIa trial to evaluate the safety and efficacy of the EP4 receptor antagonist vorbipiprant (CR6086) in combination With the PD-1 inhibitor Balstilimab (AGEN2034), in patients with pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer, and other metastatic GI cancers (2022) In: I. Agenus (Ed.)"},{"key":"4372_CR90","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1007\/s00262-011-1064-9","volume":"60","author":"D Holt","year":"2011","unstructured":"Holt D, Ma X, Kundu N, Fulton A (2011) Prostaglandin E2 (PGE2) suppresses natural killer cell function primarily through the PGE2 receptor EP4. Cancer Immunol Immunother 60:1577\u20131586","journal-title":"Cancer Immunol Immunother"},{"key":"4372_CR91","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.3389\/fimmu.2018.01859","volume":"9","author":"A Park","year":"2018","unstructured":"Park A, Lee Y, Kim MS, Kang YJ, Park YJ, Jung H et al (2018) Prostaglandin E2 secreted by thyroid cancer cells contributes to immune escape through the suppression of natural killer (NK) cell cytotoxicity and NK cell differentiation. Front Immunol 9:1859","journal-title":"Front Immunol"},{"key":"4372_CR92","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41586-024-07352-w","volume":"629","author":"M Morotti","year":"2024","unstructured":"Morotti M, Grimm AJ, Hope HC, Arnaud M, Desbuisson M, Rayroux N et al (2024) PGE(2) inhibits TIL expansion by disrupting IL-2 signalling and mitochondrial function. Nature 629:426\u2013434","journal-title":"Nature"},{"key":"4372_CR93","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41586-024-07254-x","volume":"629","author":"SB Lacher","year":"2024","unstructured":"Lacher SB, Dorr J, de Almeida GP, Honninger J, Bayerl F, Hirschberger A et al (2024) PGE(2) limits effector expansion of tumour-infiltrating stem-like CD8(+) T cells. Nature 629:417\u2013425","journal-title":"Nature"},{"key":"4372_CR94","doi-asserted-by":"publisher","first-page":"1562261","DOI":"10.3389\/fphar.2025.1562261","volume":"16","author":"Q Liu","year":"2025","unstructured":"Liu Q, Chen H, Tang D, Zhang H, Chen S, Meng Y et al (2025) Biological and prognostic insights into the prostaglandin D2 signaling axis in lung adenocarcinoma. Front Pharmacol 16:1562261","journal-title":"Front Pharmacol"},{"key":"4372_CR95","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1172\/JCI113077","volume":"80","author":"S Chouaib","year":"1987","unstructured":"Chouaib S, Robb RJ, Welte K, Dupont B (1987) Analysis of prostaglandin E2 effect on T lymphocyte activation. Abrogation of prostaglandin E2 inhibitory effect by the tumor promotor 12.0 tetradecanoyl phorbol-13 acetate. J Clin Invest 80:333\u2013340","journal-title":"J Clin Invest"},{"key":"4372_CR96","doi-asserted-by":"publisher","first-page":"1099811","DOI":"10.3389\/fonc.2023.1099811","volume":"13","author":"K Jin","year":"2023","unstructured":"Jin K, Qian C, Lin J, Liu B (2023) Cyclooxygenase-2-prostaglandin E2 pathway: a key player in tumor-associated immune cells. Front Oncol 13:1099811","journal-title":"Front Oncol"},{"key":"4372_CR97","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.11.20","author":"L Oliver","year":"2016","unstructured":"Oliver L, Olivier C, Vallette FM (2016) Prostaglandin E2 plays a major role in glioma resistance and progression. Transl Cancer Res. https:\/\/doi.org\/10.21037\/tcr.2016.11.20","journal-title":"Transl Cancer Res"},{"key":"4372_CR98","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1158\/1535-7163.MCT-09-0734","volume":"9","author":"J Wei","year":"2010","unstructured":"Wei J, Barr J, Kong LY, Wang Y, Wu A, Sharma AK et al (2010) Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther 9:67\u201378","journal-title":"Mol Cancer Ther"},{"key":"4372_CR99","first-page":"189343","volume":"1880","author":"MM Krupa","year":"2025","unstructured":"Krupa MM, Pienkowski T, Tankiewicz-Kwedlo A, Lyson T (2025) Targeting the kynurenine pathway in gliomas: insights into pathogenesis, therapeutic targets, and clinical advances. Biochem Biophys Acta 1880:189343","journal-title":"Biochem Biophys Acta"},{"key":"4372_CR100","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/cmi.2013.1","volume":"10","author":"H Harizi","year":"2013","unstructured":"Harizi H (2013) Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology. Cell Mol Immunol 10:213\u2013221","journal-title":"Cell Mol Immunol"},{"key":"4372_CR101","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.immuni.2023.05.011","volume":"56","author":"F Bayerl","year":"2023","unstructured":"Bayerl F, Meiser P, Donakonda S, Hirschberger A, Lacher SB, Pedde AM et al (2023) Tumor-derived prostaglandin E2 programs cDC1 dysfunction to impair intratumoral orchestration of anti-cancer T cell responses. Immunity 56:1341\u20131358","journal-title":"Immunity"},{"key":"4372_CR102","doi-asserted-by":"publisher","first-page":"e2350770","DOI":"10.1002\/eji.202350770","volume":"54","author":"J Cuenca-Escalona","year":"2024","unstructured":"Cuenca-Escalona J, Florez-Grau G, van den Dries K, Cambi A, de Vries IJM (2024) PGE2-EP4 signaling steers cDC2 maturation toward the induction of suppressive T-cell responses. Eur J Immunol 54:e2350770","journal-title":"Eur J Immunol"},{"key":"4372_CR103","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/bs.ai.2020.06.002","volume":"147","author":"T Bald","year":"2020","unstructured":"Bald T, Pedde AM, Corvino D, Bottcher JP (2020) The role of NK cell as central communicators in cancer immunity. Adv Immunol 147:61\u201388","journal-title":"Adv Immunol"},{"key":"4372_CR104","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.3389\/fimmu.2018.02482","volume":"9","author":"U Svajger","year":"2018","unstructured":"Svajger U, Rozman P (2018) Induction of tolerogenic dendritic cells by endogenous biomolecules: an update. Front Immunol 9:2482","journal-title":"Front Immunol"},{"key":"4372_CR105","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.cell.2018.01.004","volume":"172","author":"JP Bottcher","year":"2018","unstructured":"Bottcher JP, Bonavita E, Chakravarty P, Blees H, Cabeza-Cabrerizo M, Sammicheli S et al (2018) NK cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell 172:1022\u20131037","journal-title":"Cell"},{"key":"4372_CR106","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.taap.2009.04.015","volume":"238","author":"D Zhang","year":"2009","unstructured":"Zhang D, Hu X, Qian L, Wilson B, Lee C, Flood P et al (2009) Prostaglandin E2 released from activated microglia enhances astrocyte proliferation in vitro. Toxicol Appl Pharmacol 238:64\u201370","journal-title":"Toxicol Appl Pharmacol"},{"key":"4372_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/cells14060413","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Fuse H, Alzoubi I, Graeber MB (2025) Microglia-derived brain macrophages associate with glioblastoma stem cells: a potential mechanism for tumor progression revealed by AI-assisted analysis. Cells. https:\/\/doi.org\/10.3390\/cells14060413","journal-title":"Cells"},{"key":"4372_CR108","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/s41420-024-02077-1","volume":"10","author":"Y Zhong","year":"2024","unstructured":"Zhong Y, Liu J (2024) Emerging roles of CAR-NK cell therapies in tumor immunotherapy: current status and future directions. Cell Death Discov 10:318","journal-title":"Cell Death Discov"},{"key":"4372_CR109","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng L, Sferruzza G, Yang L, Zhou L, Chen S (2024) CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol Immunol 21:1089\u20131108","journal-title":"Cell Mol Immunol"},{"key":"4372_CR110","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.addr.2017.06.006","volume":"114","author":"JG Lyon","year":"2017","unstructured":"Lyon JG, Mokarram N, Saxena T, Carroll SL, Bellamkonda RV (2017) Engineering challenges for brain tumor immunotherapy. Adv Drug Deliv Rev 114:19\u201332","journal-title":"Adv Drug Deliv Rev"},{"key":"4372_CR111","first-page":"188957","volume":"1878","author":"HC Chen","year":"2023","unstructured":"Chen HC, Chang WC, Chuang JY, Chang KY, Liou JP, Hsu TI (2023) The complex role of eicosanoids in the brain: implications for brain tumor development and therapeutic opportunities. Biochem Biophys Acta 1878:188957","journal-title":"Biochem Biophys Acta"},{"key":"4372_CR112","doi-asserted-by":"publisher","first-page":"6840","DOI":"10.18632\/oncotarget.3160","volume":"6","author":"E Brocard","year":"2015","unstructured":"Brocard E, Oizel K, Lalier L, Pecqueur C, Paris F, Vallette FM et al (2015) Radiation-induced PGE2 sustains human glioma cells growth and survival through EGF signaling. Oncotarget 6:6840\u20136849","journal-title":"Oncotarget"},{"key":"4372_CR113","doi-asserted-by":"publisher","DOI":"10.3390\/antiox14040459","author":"FR Augello","year":"2025","unstructured":"Augello FR, Lombardi F, Ciummo V, Ciafarone A, Cifone MG, Cinque B et al (2025) COX-2 inhibition in glioblastoma cells counteracts resistance to temozolomide by inducing oxidative stress. Antioxidants. https:\/\/doi.org\/10.3390\/antiox14040459","journal-title":"Antioxidants"},{"key":"4372_CR114","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1111\/cas.16128","volume":"115","author":"W Guo","year":"2024","unstructured":"Guo W, Peng D, Liao Y, Lou L, Guo M, Li C et al (2024) Upregulation of HLA-II related to LAG-3(+)CD4(+) T cell infiltration is associated with patient outcome in human glioblastoma. Cancer Sci 115:1388\u20131404","journal-title":"Cancer Sci"},{"key":"4372_CR115","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ccell.2016.05.012","volume":"30","author":"W Hou","year":"2016","unstructured":"Hou W, Sampath P, Rojas JJ, Thorne SH (2016) Oncolytic virus-mediated targeting of PGE2 in the tumor alters the immune status and sensitizes established and resistant tumors to immunotherapy. Cancer Cell 30:108\u2013119","journal-title":"Cancer Cell"},{"key":"4372_CR116","doi-asserted-by":"publisher","first-page":"819363","DOI":"10.3389\/fncel.2022.819363","volume":"16","author":"Z Qi","year":"2022","unstructured":"Qi Z, Long X, Liu J, Cheng P (2022) Glioblastoma microenvironment and its reprogramming by oncolytic virotherapy. Front Cell Neurosci 16:819363","journal-title":"Front Cell Neurosci"},{"key":"4372_CR117","doi-asserted-by":"publisher","first-page":"9718","DOI":"10.1038\/s41467-024-54129-w","volume":"15","author":"TA Martins","year":"2024","unstructured":"Martins TA, Kaymak D, Tatari N, Gerster F, Hogan S, Ritz MF et al (2024) Enhancing anti-EGFRvIII CAR T cell therapy against glioblastoma with a paracrine SIRPgamma-derived CD47 blocker. Nat Commun 15:9718","journal-title":"Nat Commun"},{"key":"4372_CR118","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1186\/s40364-024-00679-6","volume":"12","author":"D Zhou","year":"2024","unstructured":"Zhou D, Zhu X, Xiao Y (2024) Advances in CAR-T therapy for central nervous system tumors. Biomark Res 12:132","journal-title":"Biomark Res"},{"key":"4372_CR119","doi-asserted-by":"publisher","first-page":"867154","DOI":"10.3389\/fimmu.2022.867154","volume":"13","author":"L Antonucci","year":"2022","unstructured":"Antonucci L, Canciani G, Mastronuzzi A, Carai A, Del Baldo G, Del Bufalo F (2022) CAR-T therapy for pediatric high-grade gliomas: peculiarities, current investigations and future strategies. Front Immunol 13:867154","journal-title":"Front Immunol"},{"key":"4372_CR120","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0304-3835(98)00127-X","volume":"132","author":"E Kokoglu","year":"1998","unstructured":"Kokoglu E, Tuter Y, Sandikci KS, Yazici Z, Ulakoglu EZ, Sonmez H et al (1998) Prostaglandin E2 levels in human brain tumor tissues and arachidonic acid levels in the plasma membrane of human brain tumors. Cancer Lett 132:17\u201321","journal-title":"Cancer Lett"},{"key":"4372_CR121","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10020419","author":"HC Kuo","year":"2022","unstructured":"Kuo HC, Lee KF, Chen SL, Chiu SC, Lee LY, Chen WP et al (2022) Neuron-microglia contacts govern the PGE2 tolerance through TLR4-mediated de novo protein synthesis. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines10020419","journal-title":"Biomedicines"},{"key":"4372_CR122","doi-asserted-by":"publisher","first-page":"235","DOI":"10.3389\/fncel.2018.00235","volume":"12","author":"D Matias","year":"2018","unstructured":"Matias D, Balca-Silva J, da Graca GC, Wanjiru CM, Macharia LW, Nascimento CP et al (2018) Microglia\/astrocytes-glioblastoma crosstalk: crucial molecular mechanisms and microenvironmental factors. Front Cell Neurosci 12:235","journal-title":"Front Cell Neurosci"},{"key":"4372_CR123","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00262-011-1196-y","volume":"61","author":"S Eberstal","year":"2012","unstructured":"Eberstal S, Badn W, Fritzell S, Esbjornsson M, Darabi A, Visse E et al (2012) Inhibition of cyclooxygenase-2 enhances immunotherapy against experimental brain tumors. Cancer Immunol Immunother 61:1191\u20131199","journal-title":"Cancer Immunol Immunother"},{"key":"4372_CR124","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1002\/ijc.28607","volume":"134","author":"S Eberstal","year":"2014","unstructured":"Eberstal S, Sanden E, Fritzell S, Darabi A, Visse E, Siesjo P (2014) Intratumoral COX-2 inhibition enhances GM-CSF immunotherapy against established mouse GL261 brain tumors. Int J Cancer 134:2748\u20132753","journal-title":"Int J Cancer"},{"key":"4372_CR125","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3171\/jns.2005.103.3.0508","volume":"103","author":"BT Ragel","year":"2005","unstructured":"Ragel BT, Jensen RL, Gillespie DL, Prescott SM, Couldwell WT (2005) Ubiquitous expression of cyclooxygenase-2 in meningiomas and decrease in cell growth following in vitro treatment with the inhibitor celecoxib: potential therapeutic application. J Neurosurg 103:508\u2013517","journal-title":"J Neurosurg"},{"key":"4372_CR126","doi-asserted-by":"publisher","first-page":"356","DOI":"10.3340\/jkns.2022.0267","volume":"66","author":"WS Yoon","year":"2023","unstructured":"Yoon WS, Chung DS (2023) Here is the title formatted in sentence case: advanced T and natural killer cell therapy for glioblastoma. J Korean Neurosurg Soc 66:356\u2013381","journal-title":"J Korean Neurosurg Soc"},{"key":"4372_CR127","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12061350","author":"B Reichl","year":"2020","unstructured":"Reichl B, Niederstaetter L, Boegl T, Neuditschko B, Bileck A, Gojo J et al (2020) Determination of a tumor-promoting microenvironment in recurrent medulloblastoma: a multi-omics study of cerebrospinal fluid. Cancer. https:\/\/doi.org\/10.3390\/cancers12061350","journal-title":"Cancer"},{"key":"4372_CR128","doi-asserted-by":"publisher","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","volume":"11","author":"T Shi","year":"2020","unstructured":"Shi T, Song X, Wang Y, Liu F, Wei J (2020) Combining oncolytic viruses with cancer immunotherapy: establishing a new generation of cancer treatment. Front Immunol 11:683","journal-title":"Front Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00262-026-04372-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-026-04372-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T15:03:10Z","timestamp":1775833390000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00262-026-04372-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":128,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["4372"],"URL":"https:\/\/doi.org\/10.1007\/s00262-026-04372-5","relation":{},"ISSN":["1432-0851"],"issn-type":[{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"141"}}